
For Research Use Only

DLL3 Polyclonal antibody Catalog Number:25535-1-AP 3 Publications



	Catalog Number: 25535-1-AP Size: 150ul , Concentration: 500 ug/ml by Nanodrop; Source: Rabbit Isotype: IgG Immunogen Catalog Number: AG21965	GenBank Accession Number: BC000218 GeneID (NCBI): 10683 UNIPROT ID: Q9NYJ7 Full Name: delta-like 3 (Drosophila) Calculated MW: 65 kDa Observed MW: 65-70 kDa	Purification Method: Antigen affinity purification Recommended Dilutions: WB 1:500-1:3000 IHC 1:50-1:500 IF-P 1:50-1:500
Applications	Tested Applications: WB, IHC, IF-P, ELISA Cited Applications: WB, IHC Species Specificity: human, mouse, rat	WB : I IHC :	ive Controls: mouse liver tissue, rat brain tissue human liver tissue, mouse brain tissue mouse brain tissue,
	Cited Species: human Note-IHC: suggested antigen r TE buffer pH 9.0; (*) Alternati retrieval may be performed w buffer pH 6.0	vely, antigen	
	The Delta-Notch pathway is an evolutionarily conserved signaling pathway which controls a broad range of developmental processes including cell fate determination, terminal differentiation and proliferation (PMID: 22353464). In mammals, four Notch receptors (NOTCH1-4) and five activating canonical ligands (JAGGED1, JAGGED2, DLL1, DLL3 and DLL4) have been described (PMID: 22353464). DLL3 is an inhibitory ligand of the Notch signaling pathway that is predominantly localizes to the Golgi apparatus (PMID: 17664336) in normal condition. Normal tissue expression of DLL3 is highest in fetal brain, and DLL3 plays a key role in somitogenesis in the paraxial mesoderm (PMID: 26311731). It has been reported that DLL3 is expressed on the surface of tumor cells of small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas (LCNEC) and has emerged as a novel therapeutic target (PMID: 26311731; 28487384).		
Background Information	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is h mesoderm (PMID: 26311731). It has b lung cancer (SCLC) and high-grade no	been described (PMID: 223534 ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is expl	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell
Background Information	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is h mesoderm (PMID: 26311731). It has h lung cancer (SCLC) and high-grade ne target (PMID: 26311731; 28487384).	been described (PMID: 223534 ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is expl	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell NEC) and has emerged as a novel therapeutic
	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is f mesoderm (PMID: 26311731). It has t lung cancer (SCLC) and high-grade no target (PMID: 26311731; 28487384). Author Pub	been described (PMID: 22353, ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is exp suroendocrine carcinomas (LC	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. I plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell NEC) and has emerged as a novel therapeutic Application
	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is f mesoderm (PMID: 26311731). It has t lung cancer (SCLC) and high-grade no target (PMID: 26311731; 28487384). Author Pub Qi Liu 341	been described (PMID: 22353, ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is exp euroendocrine carcinomas (LC med ID Journal	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. I plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell NEC) and has emerged as a novel therapeutic Application
	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is h mesoderm (PMID: 26311731). It has t lung cancer (SCLC) and high-grade no target (PMID: 26311731; 28487384). Author Pub Qi Liu 341 Chong Yuan 339	been described (PMID: 223534 ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is expre- suroendocrine carcinomas (LC med ID Journal 84566 Technol Canc	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. Is plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell NEC) and has emerged as a novel therapeutic Application rer Res Treat IHC IHC
	22353464). In mammals, four Notch i JAGGED2, DLL1, DLL3 and DLL4) have signaling pathway that is predomina Normal tissue expression of DLL3 is h mesoderm (PMID: 26311731). It has t lung cancer (SCLC) and high-grade no target (PMID: 26311731; 28487384). Author Pub Qi Liu 341 Chong Yuan 339	been described (PMID: 22353, ntly localizes to the Golgi app ighest in fetal brain, and DLL3 been reported that DLL3 is explored uroendocrine carcinomas (LC med ID Journal 84566 Technol Canc 15517 Transl Oncol 54616 J Immunothe er shipment. % glycerol pH 7.3.	464). DLL3 is an inhibitory ligand of the Notch baratus (PMID: 17664336) in normal condition. Is plays a key role in somitogenesis in the paraxia ressed on the surface of tumor cells of small cell NEC) and has emerged as a novel therapeutic Application ter Res Treat IHC IHC


Selected Validation Data




Various lysates were subjected to SDS PAGE followed by western blot with 25535-1-AP (DLL3 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.




Immunohistochemical analysis of paraffinembedded human liver tissue slide using 25535-1-AP (DLL3 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffinembedded human liver tissue slide using 25535-1-AP (DLL3 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed paraffin-embedded mouse brain tissue using DLL3 antibody (25535-1-AP) at dilution of 1:200 and Multi-rAb CoraLite ® Plus 488-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L) (RGAR002). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (4% PFA) fixed paraffin-embedded mouse brain tissue using DLL3 antibody (25535-1-AP) at dilution of 1:200 and Multi-rAb CoraLite ® Plus 488-Goat Anti-Rabbit Recombinant Secondary Antibody (H+L) (RGAR002). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).